R&D

Medreich is a fully integrated pharmaceutical company with an established presence across the globe. The company is involved in the CMO & CDMO business of pharmaceutical preparations in various dosage forms catering to diverse Therapeutic categories.  Medreich has an advanced state of the art Research and Development centre with proven scientific competence to develop formulations as Patent Non-infringing and Niche generics in differentiated dosage form for global regulated markets.

Across the world, countries are being challenged by the COVID-19 pandemic in ways they have never been before. Science, Engineering, and Technology will play a critical role in finding solutions to this global challenge through the development of new vaccines, devices, diagnostic tools, and information systems, as well as strategies to help communities and nations manage and deploy resources to combat this pandemic. Global challenges call for global collaborations and partnerships, bringing together the best and brightest scientists, engineers, and entrepreneurs to work together to find solutions not only to address the current pandemic, but also for the challenges that lie ahead. Collaborations and networks not only help to leverage and share expertise across S&T communities, thereby creating synergy, but often lead to the generation of innovative and transformative solutions. Collaboration, both national and international, facilitates the development of a diverse, globally-engaged science, engineering, and technology-enabled workforce.

Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs for the treatment of HIV/AIDS. Backed by over 25 years of expertise in the pharmaceutical industry, Hetero’s strategic business areas spread across APIs, Generics, Biosimilars, Custom Pharmaceutical services and Branded Generics. The company is globally recognized for its strengths in Research and Development, manufacturing and commercialization of a wide range of products.

The promulgation of Employees' State Insurance Act, 1948(ESI Act), by the Parliament was the first major legislation on social Security for workers in independent India. It was a time when the industry was still in a nascent stage and the country was heavily dependent on an assortment of imported goods from the developed or fast developing countries. The deployment of manpower in manufacturing processes was limited to a few select industries such as jute, textile, chemicals etc.

The PGIMER owes its inception to the vision of late Sardar Partap Singh Kairon, the then Chief Minister of Punjab and the distinguished medical educationists of the then combined state of Punjab, supported by the first Prime Minister of India Pt. Jawahar Lal Nehru who considered the institutions of scientific knowledge as temples of learning and the places of pilgrimage. The institute started in 1962 and Pt Jawahar Lal Nehru inaugurated the hospital now named “Nehru Hospital” on 7th July 1963.

Post : Junior Research Fellow

One of the most notable developments in the S&T sector in the XI Plan has been the setting up of the Science and Engineering Research Board (SERB) through an Act of Parliament, viz. the Science and Engineering Research Board Act, 2008. Promoting basic research in Science and Engineering and to provide financial assistance to persons engaged in such research, academic institutions, research and development laboratories, industrial concerns and other agencies for such research and for matters connected therewith or incidental thereto are the primary and distinctive mandate of the Board.

USP is proud to be an equal opportunity/affirmative action employer. Employment selection and related decisions are made without regard to sex, gender identity, race, age, disability, religion, national origin, color, veteran status or any other protected class. We are committed to working with and providing reasonable accommodation to individuals with disabilities.

Post : Scientist II CDL